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Abstract
Background: Recent observations indicate potential role of transcription factor STAT3 in cervical cancer
development but its role specifically with respect to HPV infection is not known. Present study has been designed
to investigate expression and activation of STAT3 in cervical precancer and cancer in relation to HPV infection
during cervical carcinogenesis. Established cervical cancer cell lines and prospectively-collected cervical precancer
and cancer tissues were analyzed for the HPV positivity and evaluated for STAT3 expression and its
phosphorylation by immunoblotting and immunohistochemistry whereas STAT3-specific DNA binding activity was
examined by gel-shift assays.
Results: Analysis of 120 tissues from cervical precancer and cancer lesions or from normal cervix revealed
differentially high levels of constitutively active STAT3 in cervical precancer and cancer lesions, whereas it was
absent in normal controls. Similarly, a high level of constitutively active STAT3 expression was observed in HPV-
positive cervical cancer cell lines when compared to that of HPV-negative cells. Expression and activity of STAT3
were found to change as a function of severity of cervical lesions from precancer to cancer. Expression of active
pSTAT3 was specifically high in cervical precancer and cancer lesions found positive for HPV16. Interestingly, site-
specific accumulation of STAT3 was observed in basal and suprabasal layers of HPV16-positive early precancer
lesions which is indicative of possible involvement of STAT3 in establishment of HPV infection. In HPV16-positive
cases, STAT3 expression and activity were distinctively higher in poorly-differentiated lesions with advanced
histopathological grades.
Conclusion: We demonstrate that in the presence of HPV16, STAT3 is aberrantly-expressed and constitutively-
activated in cervical cancer which increases as the lesion progresses thus indicating its potential role in progression
of HPV16-mediated cervical carcinogenesis.
Background
As the commonest cause of cancer-related female mor-
tality in developing countries and second most frequent
women malignancy worldwide, cervical cancer is the
major reproductive health problem of women globally
[1]. Several molecular and clinico-epidemiological studies
demonstrate persistent infection of high-risk human
papillomaviruses (HR-HPV) as causative agents for the
development of cervical precancer and cancer lesions [2].
Though 15 different HR-HPV types are known to
infect human genital tract and are associated with
malignant transformation, prevalence of HPV type 16
infection is exclusively very high and constitute about
50% of total HPV prevalence globally [3]. Interestingly,
HPV16 is the most common HR-HPV type associated
with cervical malignancies and is found in more than
90% of the cervical cancer cases in India [4,5]. With
annual incidence of about 132,000 and mortality of
74,000 [6], India shares one fourth of global cervical
cancer burden. Despite availability of two HPV vac-
cines directed against HPV16 and HPV18 for control
of cervical cancer [7] that have been licensed for
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clinical application in several countries including India,
it is difficult to control HPV infection through vaccina-
tion. These vaccines are not just expensive but are
only prophylactic in nature and do not possess any
therapeutic efficacy. To aggravate the scenario, until
date there is no standard therapeutic modality available
that can cure these viral infections [7]. Therefore, for
effective therapeutic intervention of HPV and to pre-
vent cervical cancer development at an early stage, it is
essential to improve understanding of molecular
mechanisms involved in HPV-mediated cervical
carcinogenesis.
Although HPV infection is essential, it is not sufficient
for ultimate tumorigenic transformation and requires
certain crucial host cell factors to regulate its viral gene
transcription. Expression of viral transforming genes, E6
and E7, of HR-HPVs is primarily regulated by cis-element
rich enhancer region termed as Long Control Region
(LCR) located upstream to its single early promoter p97
[8]. Apart from viral transcriptional regulator, E2, the
expression of viral genes/oncogenes is controlled by
host’s sequence-specific transcription factors such as
SP-1, AP-1 and NF-B, that specifically bind to the
LCR [9]. These transcription factors are normally modu-
lated at the level of expression and/or their activation.
Host transcription factors in association with viral factors
are likely to dictate viral latency, vegetative replication or
oncogenic transcription during HPV infection. Some of
these transcription factors such as AP-1 and NF-B, are
found to be up-regulated and transcriptionally active dur-
ing cervical carcinogenesis [5,10].
Signal Transducer and Activator of Transcription
(STAT) family, an important class of broad spectrum
inducible transcription factors with seven known members
plays an indispensable role in normal cellular events like
differentiation, proliferation, cell survival, apoptosis, and
angiogenesis following cytokine, growth factor and hor-
mone signaling [11]. Aberrant activation of STAT3, a
member of STAT family, has been strongly associated
with carcinogenesis and shown to promote cell cycle pro-
gression, cell proliferation and oncogenic transformation
[12]. STAT3 is activated primarily through phosphoryla-
tion at Tyr705 residue [13]. However, other post-
transcriptional modifications like phosphorylation at
Ser727 or acetylation at Lys685 are also known to inde-
pendently or simultaneously affect STAT3 activity [14,15].
Tyrosine phosphorylation is responsible for STAT3
homo- and/or hetero-dimerization and their translocation
to the nucleus, where it binds to specific consensus DNA
sequences within promoters of its downstream target
genes known to regulate apoptosis, proliferation, metasta-
sis, invasion and other important events during carcino-
genesis [16]. In addition to initial activation by tyrosine
phosphorylation, phosphorylation of STAT3 on serine
residue 727 maximally activates its transcriptional activity
[14]; whereas, STAT3 acetylation is responsible for stabili-
zation of this multi-protein-DNA complex [15,17].
Aberrant expression/activation of STAT3 has been
observed in a wide number of human cancer cell lines
and primary tumors including blood cancers and solid
tumors and has been shown to be associated with the
poor prognosis in various types of malignancies [18].
Though some studies demonstrate presence of STAT3
in a subset of cervical lesions [19-22], not much is
known about the expression and activation of STAT3
during cervical carcinogenesis in general, and its relation
to HPV infection, in particular. Recently, a potential
STAT3 binding site has been mapped on to 5’ region of
HPV16 LCR that controls expression of viral oncogenes
[23], thus suggesting a plausible productive interaction
between HPV infection and STAT3 signaling.
The cervical cancer provides a unique window of
opportunity for studying the expression of important
markers of disease progression as the tumorigenic trans-
formation of cervical epithelial cells takes 10-15 years to
occur. Cervical carcinogenesis progresses through histo-
pathologically well-characterized precursor lesions.
Keeping in view the above advantages, present study
was designed to evaluate the expression pattern of
STAT3, its phosphorylation and cellular distribution,
and DNA-binding activity in different grades of cervical
precancer and cancer lesions in relation to HPV16 infec-
tion to understand the involvement of STAT3 in
HPV16-induced cervical carcinogenesis.
Materials and methods
Cell lines and Clinical Specimens
Established cervical cancer cell lines C33a (HPV-), SiHa
and CaSki (HPV16+) and HeLa (HPV18+) cells free of
intra/inter species cross-contamination were procured
from ATCC and were maintained in prescribed culture
conditions. A total of 120 fresh cervical tissue biopsies
were collected comprising 70 malignant, 30 premalig-
nant and 20 normal (control) cervical tissues prior to
any chemo/radio therapy from the Cancer Clinic, Gynae
Out Patient Department of Lok Nayak Hospital, New
Delhi, India. Written informed consent was obtained
from all the subjects included in the study and was car-
ried out in accordance with the principles of the Hel-
sinki Declaration and clinico-epidemiological details
were taken from their clinical records. The study was
approved by the Institutional Ethics Committee. The
clinico-epidemiological characteristics are presented in
Table 1. A portion of each biopsy collected in cold 1×
phosphate buffer saline (PBS) was immediately pro-
cessed for molecular biological works and the other half
was sent for histopathological diagnosis in formalin solu-
tion. All reagents used in the study were of analytical or
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molecular biology grade and procured from Sigma
Aldrich (USA) unless specified.
Isolation of DNA and diagnosis of HPV infection
High molecular weight genomic DNA was isolated from
normal, precancerous and cancerous cervical biopsies
by the standard proteinase K digestion and phenol-
chloroform extraction procedure, and PCR amplification
was performed following the procedure described earlier
[4]. The initial HPV diagnosis was performed by using a
pair of consensus degenerate primers (MY09 and MY11)
derived from the highly conserved L1 open reading frame
of HPV genome (MY09:5’-GCMCAGGGWCATA
AYAATGG-3’, MY11:5’-CGTCCMARRGGAWACT-
GATC-3’ where M = A/C; W = A/T; Y = C/T; R = A/G).
HPV16 and HPV18 typing was done by type-specific pri-
mers [HPV16-(F) 5’-AAGGCCAACTAATAGTCAC-3’,
(R) 5’-CTGCTTTTATACTAACCGG-3’; HPV18-(F) 5’-
ACCTTAATGAAAAACCACGA-3’, (R) 5’-CGTCGT
TTAGAGTCGTTCCTG-3’]. PCR was performed in a 25
μL reaction mixture containing 50-100 ng DNA, 10 mM
Tris-HCl (pH 8.4), 50 mM KCl, 1.5 mM MgCl2, 125 mM
of each dNTPs (dATP, dGTP, dCTP, dTTP), 5 pmol of
oligonucleotide primers and 0.5 U Taq DNA polymerase.
b-globin gene was used as internal control [(F) 5’-
CAACTTCATCCACGTTCACC-3’, (R) 5’-GAAGAGC-
CAAGGACAGGTAC-3’)]. The temperature profile used
for amplification constituted an initial denaturation at
95°C for 4 min followed by 30 cycles of denaturation at
95°C for 30 sec, annealing at 55°C for 30 sec and exten-
sion at 72°C for 1 min, which was extended for 5 min at
the final cycle. Custom-synthesized, HPLC-purified pri-
mers were procured from M/s Microsynth (Germany).
Isolation of total, cytoplasmic and nuclear proteins from
cervical tissues and cell lines
Total proteins from biopsies were prepared by the method
described previously [24]. Briefly, the method involved fine
mincing of either fresh or frozen biopsies stored at -80°C,
in cold 1× PBS with surgical blade in petridish on ice. The
minced tissue material was later centrifuged at 4,000 rpm
at 4°C to wash off 1× PBS solution. For preparation of
total proteins, the pellet from minced tissue or different
cell lines (2×106 cells) was re-suspended in lysis buffer (20
mM Tris (pH 7.4), 250 mM NaCl, 2 mM EDTA (pH 8.0),
0.1% Triton X-100, 0.01 mg/ml aprotinin, 0.005 mg/ml
leupeptin, 0.4 mM PMSF, and 4 mM Na3VO4) as
described previously [25]. Lysates were spun at 14,000
rpm for 10 min to remove insoluble material. Alterna-
tively, for preparation of cytoplasmic proteins, the cell/
minced tissue pellet was resuspended in ice-cold bufferA
[20 mM HEPES pH = 7.6, 20% (v/v) Glycerol, 10 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 1 mM
PMSF, 2 mg/ml Leupeptin and 10 mg/ml Aprotinin] and
incubated on ice for 10 min with frequent vortexing.
Lysate was centrifuged at 4000 rpm for 10 min at 4°C to
obtain supernatant as cytoplasmic proteins. The remaining
pellet containing isolated nuclei was re-suspended in buf-
ferB [20 mM HEPES pH 7.6, 25%(v/v) Glycerol, 500 mM
NaCl, 1.5 mM MgCl2, 0.2 mM EDTA, 1 mM DTT, 1 mM
PMSF, 2 mg/ml Leupeptin and 10 mg/ml Aprotinin] and
centrifuged after incubation for 1 hr with repeated
Table 1 Clinico-pathological characteristics and HPV status of cervical biopsies from normal control tissues and from
cervical precancer and cancer lesions
Tissue type Characteristics Number of
samples
Total HPV+
(HPV L1)
HPV 16+ (%
positivity)
Mean age (Years; ± SD)
Normal controls 20 0 0
Normal cervical tissues without
inflammation
15 0 0 25 ± 4.6
Normal cervical tissues with inflammation 5 0 0 31 ± 3.5
Precancer 30 17 16 (53%) 29 ± 3.5
Low grade squamous intraepithelial lesions 15 7 7 (47%)
High grade squamous intraepithelial lesions 15 10 9 (60%)
Cancer Tissues 70 65 58 (83%) 50 ± 12.6
Histopathological grading Well Differentiated SCC 35 32 30 (86%)
Moderately Differentiated SCC 25 23 20 (80%)
Poorly Differentiated SCC 10 10 8 (80%)
Clinical stages Stage I 08 06 05 (63%)
Stage II 18 15 13 (72%)
Stage III 32 32 30 (94%)
Stage IV 12 12 10 (83%)
HPV - Human papillomavirus, SCC - Squamous cell carcinoma.
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vortexing on ice at 14,000 rpm for 25 min at 4°C to obtain
supernatant designated as nuclear proteins. The concen-
tration of proteins was determined by spectrophotometric
method and the proteins were stored in aliquots at -80°C
till further use.
Electrophoretic Mobility Shift Assay (EMSA)
For analysis of STAT3 DNA binding activity in tissues
or cell lines, nuclear proteins were checked by EMSA as
described earlier [26]. Briefly, 10 μg of nuclear proteins
from each sample were incubated with 32P-radiolabeled
oligonulceotide probe containing a hSIE derived from
the c-fos gene promoter (sense strand, 5’-AGCTT-
CATTTCCCGTAAATCCCTA-3’) that binds activated
STAT3 proteins [27]. Protein DNA complexes were
resolved by non-denaturating PAGE (6%). The gel was
dried and detected by Phosphoimager (FLA-5100, Fuji-
film, Japan). Quantification of STAT3 activation levels
was performed using Alpha Ease FC version 4.1.0
(Alpha Innotech Corporation, IL). Human anti-pSTAT3
specific to Phospho Tyr705 or specific to Phospho
Ser727 (BD Biosciences, USA) were used to identify
STAT3 specific DNA-proteins complexes in a super-
shift assay. For supershift analysis, 2 μg of each pSTAT3
antibody was incubated with nuclear proteins for 20
min at room temperature before the addition of radiola-
beled probe and electrophoresis. Binding specificity of
STAT3 probe was checked by using nuclear proteins of
SiHa cells with unlabelled 100× molar excess of cold
specific competitor (STAT3 probe) or mutant STAT3
oligo (data not shown) and non-specific competitor
(Oct-1).
Immunoblotting
Total cellular proteins (50 μg/lane) were separated in
8-12% polyacrylamide gel and electrotransferred on
PVDF membranes (Millipore Corp, Bedford, MA, USA).
The membrane was blocked in PBS containing 5% non-
fat skimmed milk and probed with specific antibody by
incubating the membrane overnight in pre-standardized
dilution of primary antibody in blocking solution at 4°C.
These blots were washed, incubated with HRP-anti-
mouse IgG secondary antibodies and visualized by
Luminol detection kit (Santa Cruz Biotech, USA) and by
exposing the blot to KODAK X-Omat films (Kodak
India, India). The western blot membranes were re-
probed for b-actin expression as an internal control.
The quantitative densitometric analysis of the bands was
performed using Alpha Ease FC version 4.1.0 (Alpha
Innotech Corporation, IL). The expression level of pro-
teins was quantitated on an arbitrary scale with respect
to b-actin expression where Strong (+++) - > 50%; Med-
ium (++) - 10-50%; Weak (+) - < 10% of b-actin expres-
sion; and Nil (-) - not-detectable. pSTAT3/STAT3 ratios
were determined by assessing the densitometric analysis
of bands visualized in immunoblot and normalized to
b-actin expression.
Immunohistochemistry
The immunohistochemical staining was performed as
described previously [24]. Briefly, 5 μm section of freshly
fixed and paraffinized tissue sections were deparaffinized,
rehydrated and subjected to heat-induced epitope retrie-
val in the 10 mM citrate buffer (pH 6.0). Non-specific
binding sites were blocked using 1.5% blocking serum
and incubated overnight in pre-standardized dilution of
primary antibody. Immunoreactivity was visualized
according to manufacturer protocol (ABC staining kit,
Santa Cruz Biotech).
Histopathological and immunohistochemical evaluation
The Bethesda system of classification was used in the
present study for the histopathological grading of cervi-
cal precancer and cancer cases [28]. Two independent
pathologists performed the histopathological evaluation
of hematoxylin and eosine-stained tissue sections as per
routine procedure. Scoring of IHC staining was per-
formed by three independent investigators (SS, SH and
ACB). In case of sections from normal tissues and
LSILs, basal and suprabasal epithelial cells were analyzed
for STAT3/pSTAT3 immunostaining; whereas for
HSILs, basal, suprabasal, and intermediate layers of
epithelial cells were analyzed. In cancer cases, all the
cells were analyzed for STAT3/pSTAT3 immunostain-
ing. Overall inter-observer difference varied between 5-
10%. Discrepant scores were resolved by joint evaluation
and consensus. Every IHC-stained tissue was scored as
reported earlier [24,29] on an arbitrary scale according
to the number of positively stained cells and overall
staining intensity of the section and assigned a value
ranging from Nil (-) - no staining; Weak (+) - 1-10%
cells showing focal positivity; Moderate (++) - 11-50%
cells showing focal positivity; and, Strong(+++) - more
than 50% cells showing diffused positivity.
Analysis of STAT3 mRNA expression by reverse
transcription-PCR
Total RNA was isolated from cervical cancer cell lines
and from a subset of cervical normal (n = 5), precancer
(n = 8) and cancer tissues (n = 10) by TRI reagent(r) as
per manufacturer’s instruction (Sigma-Aldrich Inc,
USA). The quality and integrity of RNA was checked
spectrophotometrically and on 1.0% agarose gel. For
reverse transcription-PCR (RT-PCR) analysis, 3 μg of
total RNA was subjected to reverse transcription using
Omniscript RT-PCR kit (Qiagen, USA) to prepare the
cDNA. For the amplification of STAT3 mRNA, the
primer pairs 5’-TTGCCAGTTGTGGTGATC-3’and
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5’-GAACCCAGAAGGAGAAGC-3’ were used with the
following conditions: 94°C for 5 min, then 30 cycles of
94°C for 30 sec, 55°C for 30 sec, and 72°C for 1 min,
followed by 72°C for 5 min that resulted in amplicon of
318 bp size [30]. Amplification of GAPDH (forward
5’-TGGATATTGTTGCCATCA ATGACC-3’; reverse
5’-GATGGCATGGACTGTGGTCATG-3’) transcripts
from the respective cDNAs was used as an internal con-
trol (520 bp). The PCR products were analyzed on 3%
agarose gel.
Statistical analysis
The data analysis was performed using the statistical
software Sigma Stat Graph Pad Instat (version 4.0).
Fisher’s Exact Test (for smaller numbers on subgroup
analysis), t-test or chi square were used to compare the
expression of proteins among different histopathological
grades of tissue biopsies. p values of <0.05 were consid-
ered statistically significant.
Results
Established cervical cancer cell lines (C33a, SiHa, CaSki,
HeLa) and 100 prospectively collected biopsies from pre-
cancer and cancer lesions and 20 control specimens from
histopathologically-confirmed, normal hysterectomized
cervix were examined for presence of HPV infection as
well as expression and activation of STAT3. Clinico-
pathological characteristics, demographical details of the
cases and controls and status of HPV infection in corre-
sponding tissues is presented in Table 1.
Detection of HPV DNA sequences in cervical precancer
and cancer tissues
To determine the status of HPV infection and distribu-
tion of HPV16/18 types in study samples, HPV L1 and
type-specific PCRs were performed as described in
Methods. PCR-based detection revealed HPV infection
in 17 out of 30 cases (57%) of precancer lesions and 65
out of 70 cases (92%) of cancer lesions (Table 1). All
normal control tissues were confirmed HPV negative.
Out of 82 tissues positive for HPV L1 sequences, 13 out
of 17 precancer (76%) and 58 out of 65 cancer (89%) tis-
sues were found to contain HPV16 infection, whereas,
in 1 (6%) precancer and 9 (13%) cancer cases HPV18 or
other high-risk HPV infections were detected. Distribu-
tion of HPV16 positive cases was similar across different
histopathological grades and clinical stages.
STAT3 expression and phosphorylation in cervical cancer
cell lines and tumor biopsies
To determine STAT3 expression and its phosphoryla-
tion at Y705 and S727 residues in cervical cancer, HPV
positive [SiHa & CaSki (HPV16+) and HeLa (HPV18+)]
and HPV- cervical cancer cell lines (C33a) were tested
for expression of STAT3 and pSTAT3 (Y705 & S727)
by immunoblotting. As shown in Figure 1A, immuno-
blot analysis of cellular proteins demonstrated constitu-
tive STAT3 expression in all cervical cancer cell lines
although the degree of expression was variable. In con-
trast to HPV- C33a cells, all HPV positive cells had
higher expression of STAT3. These cellular proteins
were simultaneously tested for expression of phosphory-
lated STAT3 at Y705 & S727 by monoclonal antibodies
that could distinguish between the two phosphorylated
forms of STAT3 from each other. Interestingly, all four
cell lines irrespective of HPV infection expressed
STAT3 phosphorylated at Y705 & S727 residues, though
HPV16+ cells expressed a comparatively higher level of
phosphorylated forms in comparison to HPV- (C33a) or
HPV18+ (HeLa) cells.
Further, we examined the expression and phosphoryla-
tion of STAT3 in cervical precancer and cancer tissues and
compared with normal controls. As shown in Figure 1B
and (Additional file 1: Table S1), only trace amounts of
STAT3 were expressed in normal cervical tissues whereas
both low grade as well as high grade precancer lesions
(LSIL and HSIL) expressed either moderate or high
levels of STAT3 respectively. STAT3 was consistently
over-expressed in cancerous tissues (Additional file 1:
Table S1). Immunoblotting for pSTAT3(Y705) and
pSTAT3(S727) revealed a concordant increase in pSTAT3
levels in precancer and cancer lesions indicating that
STAT3 expressed in these lesions was phosphorylated both
at Y705 and S727 residues. The expression of STAT3 and
its phosphorylated forms was found to increase as a func-
tion of severity of the cervical lesions from precancer to
cancer stages.
To assess whether STAT3 is also elevated at mRNA
level, the total RNA isolated from cervical cancer cell
lines or from a subset of cervical tissues comprising nor-
mal, precancer (LSIL and HSIL) and cancer lesions were
subjected to cDNA synthesis and STAT3-specific RT-
PCR. As shown in Figure 1C, both HPV positive cervical
cancer cell lines as well as HSIL and cancer tissues
expressed high levels of STAT3 transcripts. On the
other hand, level of STAT3 transcript was moderate in
HPV negative cell line C33a and LSILs while it was not
detectable in normal tissues.
Increased expression and nuclear localization of STAT3
and phosphorylated STAT3 in cervical precancer and
cancer lesions
Though immunoblotting provides an average data, a
potential pitfall of the analysis using tissue samples is
contribution of “contaminating” cells (e.g. stromal and
inflammatory cells) to the level of STAT3 or pSTAT3
expression. Therefore, to evaluate micro-heterogeneity
in the expression and cellular distribution of STAT3 in
Shukla et al. Molecular Cancer 2010, 9:282
http://www.molecular-cancer.com/content/9/1/282
Page 5 of 17
precancer and cancer tissues in situ, immunohistochem-
ical protocol was optimized for analysis of STAT3,
pSTAT3(Y705) and pSTAT3(S727) in freshly-collected,
paraffinized tissue sections. As indicated in Figure 2 and
(Additional file 2: Table S2), immunohistochemical ana-
lysis demonstrated complete absence of phosphorylated
(Y705 or S727) or non-phosphorylated STAT3 in nor-
mal tissues (Figure 2, upper panel), however, a few
Figure 1 Cervical cancer cells over-express STAT3 with phosphorylation on both tyrosine and serine residues. (A) Cervical cancer cell
lines C33a (HPV-), SiHa & CaSki (HPV16+) and HeLa (HPV18+) (2 × 106 cells) were lysed, and 50 μg of total cellular proteins were resolved on
7.5% SDS-PAGE, electrotransferred to a PVDF membrane, and probed for STAT3, pSTAT3(Y705), pSTAT3(S727) and b-actin expression by
respective antibodies. (B) STAT3 expression and phosphorylation increases as a function of severity of cervical lesions. Representative immunoblot
of STAT3, pSTAT3(Y705), pSTAT3(S727) and b-actin indicating expression of respective protein in total cellular proteins (50 μg) isolated from
normal (N), low grade squamous intra-epithelial lesion (LSIL1 & 2), high grade SIL (HSIL) and cervical cancer biopsy tissues (CaCx1, CaCx2) as
described in Methods. (C) STAT3 RT-PCR analysis of cDNA derived from cervical cancer cell lines and cervical tissues. Representative ethidium
bromide-stained agarose gel (3%) showing specific amplification STAT3 transcripts (318 bp) in the cDNA derived from total RNA of indicated
samples (middle panel). Quality and quantity of RNA used for cDNA preparation was examined and confirmed by 1% agarose gel electrophoresis
(upper panel). GAPDH RT-PCR (amplicon size 520 bp) was used as internal control (lower panel).
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control tissues with inflammatory cytology demonstrated
low or moderate immunopositivity for STAT3 and
pSTAT3 (data not shown). Majority of the low grade
precancer lesions (LSIL) had low or undetectable
STAT3 or pSTAT3 expression, though in some LSIL,
STAT3 and pSTAT3 showed focal positivity in both
basal and suprabasal layers that was found to be equally
distributed among nuclei and cytoplasm (Figure 2, mid-
dle panels). In contrast, high grade precancer lesions
(HSIL) had variable level of STAT3 and pSTAT3
expression that frequently localized to the nuclei. Of 50
cancer biopsies examined for immunohistochemical ana-
lysis of STAT3, 42 were found positive for STAT3 and
out of these, 71% had either moderate or high STAT3
expression and had variable degree of nuclear positivity
[(Figure 2, lower panels) and (Additional file 2: Table
S2)]. Moreover, low levels of STAT3, pSTAT3(Y705)
and pSTAT3(S727) were also detectable in the cyto-
plasm. Interestingly, STAT3 and pSTAT3(Y705) expres-
sion as well as nuclear localization were concordant in
majority of cancer tissues, however, degree of pSTAT3
(S727) expression and its nuclear localization, in general,
was lower than that of STAT3 that could be attributed
to variability in affinity of different antibodies.
Constitutive activation of STAT3 in cervical cancer cell
lines and tumor biopsies
To evaluate DNA binding activity of overexpressed,
nuclear STAT3/pSTAT3 and to confirm its constitutive
activation in cervical cancer, we performed EMSA analy-
sis of nuclear proteins derived from human cervical can-
cer cell lines, C33a, SiHa and CaSki and a subset of
freshly collected biopsies from normal, precancer and
cancer lesions. Figure 3A, shows presence of active
STAT3 complexes in both HPV negative and HPV16
positive cervical cancer cell lines. Compared to HPV-
C33a cells, HPV16+ SiHa and CaSki cells showed mar-
ginally higher DNA-binding activity. Binding of hSIE
probe to STAT3 was found to be specific as antibody to
pSTAT3 could specifically bind and supershift retarded
DNA-protein complex, confirming that the activity cor-
responds to STAT3 (Figure 3B). On the other hand,
normal cervical tissues expressed low or undetectable
STAT3 DNA binding activity except in a few cases that
had inflammatory cervix (Figure 3C, N1 and N2 respec-
tively). In comparison, precancer lesions (both LSIL and
HSIL) showed moderate STAT3 DNA binding, whereas,
cancer biopsies revealed a prominent STAT3 activity
(Figure 3D). When Oct-1 was used as a probe, which
served as a control, there was no difference in DNA
binding activity between normal, LSIL/HSIL or cancer
(Figure 3E), thus indicating that increased expression
and activation of STAT3 is specific to the process of
cervical carcinogenesis.
Association of HPV16 infection with STAT3/pSTAT3
expression in cervical precancer and cancer lesions
To analyze the effect of HPV16 infection on STAT3
expression and activity in different stages of cervical car-
cinogenesis, the STAT3/pSTAT3 immunoblotting data
of precancer and cancer lesions were reanalyzed with
respect to the status of HPV infection in the respective
lesion. As shown in Table 2, HPV16+ cervical precancer
and cancer tissues expressed a higher level of STAT3
and pSTAT3(Y705) as compared to that in the HPV-
precancer and cancer lesions. One precancer (HSIL)
and 7 carcinoma samples that were HPV L1+ but
HPV16- were excluded from the analysis to avoid HPV
type as a confounding variable. Nonetheless, these tis-
sues also showed similar over-expression of active
pSTAT3/STAT3. Majority of HPV- precancer, cancer
and normal tissues lacked expression of STAT3 and
pSTAT3 while only a small number of HPV16+ precan-
cers (n = 6/16; 37%) and cancers (n = 12/58; 21%) had
no or low STAT3 expression. Interestingly, immunohis-
tochemical analysis of precancer lesions particularly of
LSILs showed a focal positivity of STAT3 and when
these cases were analyzed with respect to their HPV16
status they showed a low background staining with no
nuclear positivity for STAT3 as well as pSTAT3 in HPV
negative LSIL sections (Figure 4). In contrast, HPV16
positive LSIL sections revealed a strong focal positivity
and nuclear localization of both STAT3 and pSTAT3
(Y705 & S727) in basal and suprabasal cell layers of cer-
vical epithelium.
Differential expression and activation of STAT3 in various
histopathological grades of the HPV16 positive cancer
lesions
Since STAT3 expression/activation was localized in
HPV16+ precancer lesions. To determine its correlation
we examined STAT3 expression in HPV16+ cervical
cancer cases with different histopathological grades.
Forty five (n = 45) cancer biopsies with confirmed histo-
pathology and HPV16 positivity were re-evaluated for
STAT3 and pSTAT3 expression. As shown in Figure 5A
and 5B, a comparative immunoblotting and immunohis-
tochemical analysis revealed a lower expression of
STAT3 and pSTAT3 (both Y705 and S727) in WDSCC
cases in comparison to MDSCC and PDSCC that had
high STAT3 and pSTAT3 expression. Elevated level of
pSTAT3 in MDSCC and PDSCC were also corroborated
with intense nuclear positivity of STAT3 in histologi-
cally-advanced cancer tissues and was found in as high
as 78% and 88% of cancer cells in MDSCC and PDSCC
respectively. In contrast, only in 53% of cells in WDSCC
sections showed nuclear localization of STAT3 proteins
(Figure 5C). Together, these findings indicate that con-
stitutive activation of STAT3 is a frequent occurrence in
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Figure 2 Increased expression and nuclear localization of STAT3 and pSTAT3 in cervical precancer and cancer lesions. Representative
photomicrographs of immunohistochemical analysis of STAT3, pSTAT3(Y705) and pSTAT3(S727) in normal, precancer (LSIL & HSIL) and cancer
lesions. Freshly fixed, paraffin-embedded sections (5 μm) of cervical tissues from normal, precancerous and cancerous lesion of the cervix were
processed for IHC and probed for STAT3, pSTAT3(Y705) and pSTAT3(S727) with respective antibodies and detected by HRP-DAB method as
described in Methods. Brown precipitate indicates immuno-positive cells, blue stain represent nuclei and co-localization of brown and blue stain
represents nuclear localization of STAT3 and pSTAT3. (Original magnification: 200×).
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Figure 3 STAT3 is constitutively active during cervical carcinogenesis. (A) Cervical cancer cell lines C33a, SiHa and CaSki express
constitutively active STAT3 DNA-binding activity. Ten μg of nuclear proteins of respective cell line were incubated with 32P-radiolabeled STAT3
probe and resolved on 6.0% non-denatunating PAGE. (B) Gel supershift assay showing specificity of STAT3 binding. SiHa cell nuclear proteins (10
μg) were incubated for 30 min with pSTAT3(Y705) or pSTAT3(S727) antibodies (2 μg each) or pre-immune serum (PIS) and assayed for STAT3
binding activity by EMSA. STAT3-specific complex and super-shifted bands after antibody addition is indicated. (C) Constitutive STAT3 activation
in cervical precancer and cancer lesions. Nuclear proteins (10 μg) prepared from normal (N1 & N2*), precancer (LSIL and HSIL) and cancer lesions
(Ca1 & 2) were tested for presence of STAT3 DNA binding activity by EMSA. The extent of STAT3 activity increased as a function of severity of
the disease. Cancerous lesions showed high STAT3 binding activity. N2* showed inflammatory cytology. (D) Nuclear proteins were
simultaneously checked for equal loading using EMSA for constitutively active transcription factor Oct-1 that showed uniform binding in different
tissues types. (E) Mean fold change in STAT3 DNA binding activity in cervical precancer and cancer lesions with respect to normal controls. Error
bars indicate standard deviation. ap value < 0.001 versus normal control tissues; bp value < 0.001 versus precancer tumor tissues as determined
by t-test.
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Table 2 Expression of STAT3 and phosphorylated STAT3 [pSTAT3(Y705) and pSTAT3(S727)] in HPV- and HPV16+ precancer and cancer lesions of the uterine
cervix as observed by immunoblotting1
Target Protein Normal (n = 20) Precancer (n = 29) Cancer (n = 63) p value
HPV- (n = 20); (%) HPV- (n = 13); (%) HPV16+ (n = 16); (%) HPV- (n = 5); (%) HPV16+ (n = 58); (%)
Expression Level (®) N(-)/W(+) M(++)/S(+++) N(-)/W(+) M(++)/S(+++) N(-)/W(+) M(++)/S(+++) N(-)/W(+) M(++)/S(+++) N(-)/W(+) M(++)/S(+++)
STAT3 18
(90%)
2
(10%)
12
(92%)
1
(8%)
6
(37%)
10
(63%)
4
(80%)
1
(20%)
12
(21%)
46
(79%)
0.005a, 0.01b, 0.49c, 0.19d
pSTAT3 (Y705) 19
(95%)
1
(5%)
12
(92%)
1
(8%)
8
(50%)
8
(50%)
4
(80%)
1
(20%)
21
(36%)
37
(64%)
0.01a 0.07b
0.49c
0.47d
pSTAT3
(S727)
19
(95%)
1
(5%)
12
(92%)
1
(8%)
8
(50%)
8
(50%)
4
(80%)
1
(20%)
28
(48%)
30
(52%)
0.11a
0.37b
0.49c
0.87d
1Arbitrary level of expression in immunoblotting: Strong (S) = (+++); Medium (M) = (++); Weak (W) = (+); Nil/not detectable (N) = (-). Values indicate the distribution of specimens in each category.
p value, probability from Fischer’s Exact Test comparing the expression of proteins; aHPV- vs HPV16+ precancer cases, bHPV- vs HPV16+ cancer cases, cHPV- Precancer vs HPV- in cancer cases, dHPV16+ Precancer vs
HPV16+ cancer cases.
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high grade malignant cervical carcinomas and positively
correlated with poorer histopathological grades.
Discussion
In the present study, we demonstrate aberrantly
expressed and constitutively active STAT3 both in cervi-
cal cancer cell lines and in cervical precancer and cancer
lesions. Expression of STAT3 was elevated at transcript
level and was found associated with simultaneous
increase in phosphorylation at both, Tyr705 and Ser727,
that are known to regulate STAT3 dimerization, nuclear
transport, DNA-binding and transactivation. Dually
phosphorylated STAT3 present in cervical precancer and
cancer lesions was found to localize to the nuclei and
possessed a functional DNA-binding activity. Our immu-
noblotting, IHC and DNA binding assays revealed that
aberrant STAT3 activity increases as a function of sever-
ity of the disease from precancer to cancer during cervi-
cal carcinogenesis and was found associated with HPV16
positive lesions. Moreover, STAT3 expression and activa-
tion correlated well with HPV16 positivity in cervical pre-
cancer and cancer lesions which indicates its possible
involvement in establishment of HPV infection and per-
sistence. In addition, when correlated with different
histopathological grades in HPV16 positive cancer
lesions, cases with more advanced histopathological
grades had significantly higher expression of active
STAT3.
In precancer lesions, we observed STAT3 immunoposi-
tivity ranging from 10 to 25% by IHC and about 33-40%
by immunoblotting. STAT3 positivity, irrespective of the
technique, was consistently higher than pSTAT3(Y705)
and pSTAT3(S727) indicating a smaller proportion of
STAT3 pool could be in unphosphorylated state. Simi-
larly, pSTAT3(S727) was under-represented indicating
potentially lesser phosphorylation at serine residue. How-
ever, validity of such claim(s) cannot be ascertained, as
stoichiometry of antibody-binding is likely to be variable
due to difference in affinity of various STAT3 antibodies.
Alternately, it is possible that a discrepantly larger pro-
portion of tumors showing high level of STAT3 but with
lower pSTAT3 levels may have a major pool of STAT3
that could be in non-phosphorylated state and might be
activated by alternate mechanisms like acetylation at
Lys685 which reportedly activates STAT3’s sequence-
specific DNA-binding and subsequent activation
independent of tyrosine phosphorylation [15,17]. Our
observations indicating a potential role of STAT3 in cervical
Figure 4 Localized overexpression of STAT3 and pSTAT3 in basal layer of early precancer lesions positive for HPV16 .
Immunohistochemical analysis of STAT3, pSTAT3(Y705) and pSTAT3(S727) expression in HPV negative and HPV16 positive LSILs. White arrows
indicate absence of STAT3 expression in basal layer of HPV negative lesions. STAT3 and pSTAT3 showed focal positivity and were localized in the
nuclei in HPV16 positive LSIL tissues (marked by black arrows).
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carcinogenesis have been supported by similar results from
others demonstrating presence of pSTAT3 in nuclei of cer-
vical neoplastic cells, though with variable levels of expres-
sion ranging from 24% to 56% [19-22] (Table 3). These
studies were primarily conducted using pSTAT3 IHCs on
retrospectively collected specimens. About 40% STAT3
nuclear positivity has been demonstrated in cervical precan-
cer lesions [21,22], which predominantly were of HSILs
category (CIN2 and CIN3). Our results show a higher
STAT3 positivity in HSIL compared to LSIL (CIN1) type of
precancer lesions, but the difference was not statistically sig-
nificant (data not shown). In contrast to moderate immuno-
positivity in precancer lesions, more than 70% cancer
biopsies examined expressed moderate to high levels of
STAT3 which was supported by both pSTAT3 IHC as well
as immunoblotting. Earlier reports showed presence of
pSTAT3 in cervical cancer tissues albeit to a much lesser
level (24%) [19] that could be due to the use of preserved
Figure 5 Differential expression of STAT3 and pSTAT3 in various histopathological grades of the HPV16 positive lesions during
cervical carcinogenesis. (A) Representative immunoblots showing expression pattern of STAT3 and pSTAT3 proteins in well differentiated
(WDSCC), moderately differentiated (MDSCC) and poorly differentiated (PDSCC) squamous cell carcinoma nuclear proteins with densitometric
ratio of pSTAT3: STAT3 expression. (B) Representative photomicrographs showing differential expression and nuclear localization of STAT3 on
paraffin embedded sections of HPV16+ invasive cervical cancer tissues in various histopathological grades. C. Cumulative data of
immunohistochemical evaluation of degree of STAT3 over-expression and nuclear localization which increases as a function of severity of the
disease. 1Values indicate percentage of specimens showing either medium or strong overall STAT3 expression on an arbitrary staining intensity
grading as described in Methods. 2Percent number of cells showing nuclear positivity in specimen expressing medium or strong STAT3
expression. p value < 0.001 versus values for WDSCCa or MDSCCb as determined by Fischer’s Exact Test/Chi Square test. p value < 0.001 versus
values for WDSCCc or MDSCCd as determined by t-test.
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Table 3 Comparative analysis of studies examining expression of STAT3 and phosphorylated STAT3 in cervical precancer and cancerous lesions
Study (Year) Tissues Type of
study
Immunohistochemistry
(% positivity)
Immunoblotting
(% positivity)
STAT3
DNA
Binding
Correlation
with HPV
positivity
Precancer (n) Cancer (n) STAT3 pSTAT3 (Y705) pSTAT3 (S727) STAT3 pSTAT3 (Y705) pSTAT3 (S727)
Yang et al. (2005) 56 - Retrospective ND ND 42% (24/56)a ND ND ND ND ND
Yang et al. (2006) 56 - Retrospective 39% (22/56)a ND ND ND ND ND ND ND
Chen et al. (2007) - 104 Retrospective ND 24% (25/104)b 23% (24/104)b ND ND ND ND ND
Takemoto et al. (2009) - 125 Retrospective ND 57% (71/125)b ND ND ND ND ND ND
Shukla et al.
(present study)
30 70 Prospective 25% (5/20)a
71% (30/50)b
20%
(4/20)a
56% (28/50)b
10%
(2/20)a
40% (20/50)b
40%
(12/30)a
71%
(50/70)b
33% (10/30) a
57% (40/70) b
33% (10/30) a
45% (32/70)b
Yes Yes
aPrecancer tissues, bCancer tissues; ND - not determined.
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tissue blocks or tissue arrays. Similarly, in a recent report,
with lower stringency of analysis by considering 10% cells
expressing nuclear pSTAT3 as cut off for positives, a maxi-
mum of 57% STAT3 positivity was observed in cervical
cancer tissues [20]. A higher STAT3 expression and activa-
tion found in our study could be either due to the variations
in histologic subtype, definition of positive expression or the
improved quality of sample as they were processed immedi-
ately. STAT3 being a labile protein and since the specimen
for earlier studies were archived samples, it is quite likely
that due to prolonged storage STAT3 might have under-
gone degradation or dephosphorylation which may in part
be responsible for the low levels of pSTAT3 expression.
Moreover, the studies reported earlier had used only IHCs
for pSTAT3 and did not examine total STAT3 expression
simultaneously. It is important to note that phosphorylation
level of STAT3 is critically influenced by the processing
time following tissue resection. Prolonged delay in the fix-
ing or freezing of tissue specimens has been shown to
reduce phosphorylation level of STAT3 due to the activity
of tyrosine phosphatases [31]. Moreover, all earlier studies
did not correlate STAT3 expression in cervical lesion with
the status of HPV infection, the principle agent that cause
cervical cancer. Increased STAT3 expression/activation in
present study may also be associated with geographical var-
iations in the spectrum of incident HPV infection. As
reported earlier [4], HPV16 is the most prevalent HR-HPV
type in cervical cancer of Indian women and in present
study also we observed a high frequency of HPV16
sequences in about 83% of cancers and 53% in precancer
tissues. This is much higher prevalence of HPV16 in cervi-
cal cancer than that from other Asian countries which
ranges from 45%-52% [32,33].
Appearance of activated STAT3 in early precancers
and especially those with HPV16 infection and its speci-
fic localization in basal and suprabasal cells (Figure 4)
which represent the proliferating compartment of an
epithelium in which transformation process takes place
and is the site of productive HPV infection, clearly
reflects a possible involvement of STAT3 in establish-
ment of persistent viral infection in HPV infected
lesions. Interestingly, recent study identifying cancer
stem-like cells from primary cervical carcinoma also
demonstrated high expression of STAT3 mRNA in all
of the sphere-forming stem cells [34]. Not surprising,
constitutive STAT3 expression and its activation, to
some extent, were also observed in some of the normal
tissue with inflammatory cytology (Figure 3C lane N2).
It is likely that, inflammation caused by primary infec-
tion with sexually transmitted pathogens like Chlamydia
trachomatis, may enhance STAT3 activation which may
further support HPV infection and persistence. Sexually
transmitted infections like Neisseria gonorrhea, Chlamy-
dia trachomatis, and Herpes Simplex virus 2 have also
been shown to act as cofactors for cervical cancer devel-
opment [35-37] and are often associated with an intense
chronic inflammatory response and microulcerations in
the cervical epithelium [38] that cause exposure of the
basal cell layer of the epithelium to infectious HPV vir-
ions and subsequent viral entry.
Present study demonstrated a significant correlation
between HPV16 positivity and overexpression of STAT3
and pSTAT3 in cervical precancer and cancer lesions.
Interestingly, some of the HPV16+ precancers and can-
cer cases particularly the lesions with WDSCC histo-
pathology showed a lower level of STAT3/pSTAT3
expression and nuclear positivity. Although HPV16 posi-
tivity among various histopathological grades (WDSCC,
MDSCC, PDSCC) differed only marginally (86%, 80%,
80% respectively) it did not similarly correlate with
STAT3 expression or nuclear localization. Histopatholo-
gically more advanced HPV16+ PDSCC cases expressed
higher levels of nuclear localized STAT3 in comparison
to HPV16+ WDSCC cases. This reflects that mere pre-
sence of viral DNA in host cells does not induce STAT3
activity but requires expression of viral genes/oncogenes
to interact with host cell signaling that governs activa-
tion of STAT3 signaling cascade and the absence of
these factors may result in diminished STAT3 activity.
Moreover, physical state of viral DNA (integrated versus
episomal) and the copy number of the virus that influ-
ence the magnitude of viral oncogene expression [39,40]
could be the important factors responsible for variable
cellular response with respect to levels of STAT3 activ-
ity. However, these upstream mechanisms are yet to be
investigated.
Constitutively active STAT3 has been shown to be
associated with higher histological grades and invasive
cancer in several epithelial and other malignancies
[12,18]. Although the reasons for aberrant STAT3 activ-
ity in cervical precancer and cancer lesions remains to be
investigated, its association with HPV16 infection in cer-
vical carcinogenesis is evident from data presented in the
present study. Studies indicate high viral oncogenes E6/
E7 mRNA expression or increased viral genomes/cell
strongly relate to advanced histopathological grades that
favor poor prognosis [41,42]. Similarly, STAT3 has also
been shown to be a poor prognostic factor in cervical
cancer by other investigators [20]. The relation between
increased STAT3 expression with HPV16 copy number
or its oncogene expression is currently not known,
though several lines of evidence suggest a possible inter-
action between these two regulatory arms of cervical car-
cinogenesis. Similar to HPV E7 induced transformation
in cervical cells by targeting retinoblastoma (Rb) activity
[43], Simian Virus 40-induced transformation caused by
inactivation of pRB through its large T antigen has been
shown to result in upregulation of STAT3 [44]. On the
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other hand, p53 and STAT3 have been shown to antago-
nize expression of each other as p53 prevents the effect
of STAT3 on cell transformation [45] and STAT3 down-
regulates the expression and function of p53 by binding
to the p53 promoter and resulting in decreased de novo
expression of p53 [46]. These observations indicate that
aberrantly expressed STAT3 that drive oncogenic trans-
formation could be a potential outcome of E6/E7-
mediated de-stabilization of p53/pRB-mediated cell cycle
regulatory loop that keeps negative control over STAT3
expression. Indeed, our recent observations do indicate
an increased STAT3 mRNA expression in cervical can-
cers [47] which was also validated in the current study.
Current findings demonstrate that these transcription-
ally-overexpressed STAT3 transcripts are significantly
translated as functional proteins which are simulta-
neously activated through phosphorylation events and
may be playing an important role in driving HPV16
mediated cervical carcinogenesis.
We observed a constitutively active STAT3 in cervical
cancer cases which increased as a function of disease
severity. STAT3 activity is regulated by two independent
phosphorylation, at Tyr705 and at Ser727 which are
required for its fully functional activity [14]. Tyr705
phosphorylation primarily controlled by STAT3
upstream kinases, JAK, Src and EGFR or its negative
regulators like phosphatases PTEN, SOCS and PIAS,
whereas Ser727 phosphorylation is regulated by MAP/
JNK pathway [48] that is commonly activated in stress
response and chronic inflammation. However, there is
no report that directly or indirectly demonstrates the
interaction of HPV oncogenes with these positive or
negative regulators of STAT3 activity. Since chronic
inflammation is the precursor of majority of cancers
[49], a likely-hood of increased expression of various
inflammatory cytokines due to HPV infection cannot be
ignored in cervical carcinogenesis. Inflammatory cyto-
kine IL-6, a potent inducer of STAT3 activity through
binding to gp130 associated receptors and Jak/Tyk
kinases, has received particular attention in the patho-
genesis of cervical cancer. Non-malignant HPV-
transformed keratinocytes and cervical carcinoma cells
produce large quantities of IL-6 [50]. However, studies
show that IL-6 may not be working in the autocrine
manner as the cervical cells tend to lose the IL-6 recep-
tor [50]. Therefore, constitutive activation of STAT3
could be an IL-6-independent event promoted by alter-
nate signaling pathway. Studies indicate high expression
of epidermal growth factor receptor (EGFR) RNA in
three dimensional organotypic cultures of human cervical
carcinoma cells and blocking EGFR functions by a speci-
fic and reversible inhibitor, PD153035, decrease the DNA
synthesis and inhibited invasion in a dose-dependent
manner [51]. EGFR has been shown to initiate multistage
skin carcinogenesis in murine models through activation
of STAT3 [52] and ErbB2 and EGFR family receptors
have been demonstrated to be frequently amplified in
squamous cell carcinoma of uterine cervix [53,54]. An
increased STAT3 activation observed in HPV-infected
cells could be due to constitutive activation of EGFR
[55]. Alternatively, epigenetic alternations of expression
of negative regulators like PTEN, SOCS3 or PIAS could
be another possible reason for aberrantly activated
STAT3. In low risk HPV6/11-associated laryngeal papil-
lomas, presence of a moderate or low level pSTAT3
(Tyr705) was detected in non-anogenital papillomas
which was attributed to the increased expression of its
negative regulator, PTEN [56]. Interestingly, PTEN
methylation and loss of PTEN expression are early events
in the development of cervical cancer [57]. Our prelimin-
ary investigations looking into the promoter methylation
of SOCS and PIAS gene has revealed significantly higher
methylated promoter in cervical precancer and cancer
lesions (unpublished observation) which is being investi-
gated further.
Overall present study demonstrates an aberrant
expression and constitutive activation of STAT3 in cer-
vical carcinogenesis that accumulates gradually during
the process of cervical carcinogenesis and describes a
significant correlation of high risk HPV16 infection in
cervical lesions with active STAT3 expression. However,
the interaction of HPV16 or its oncogenes with STAT3
signaling in cervical cancer and the mechanism of
HPV16-mediated STAT3 activation is yet to be eluci-
dated. Understanding mechanism of disease pathogen-
esis particularly focusing on interaction of HPV genes/
oncogenes with STAT3 signaling may help in develop-
ment of novel approaches for therapeutic interventions
against HPV infection and cervical cancer.
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